A phase I study of TKI258 and capecitabine in patients with advanced pancreatic cancer and treatment failure after first-line chemotherapy - CAPDOV
Phase of Trial: Phase I
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Dovitinib (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms CAPDOV
- 17 Mar 2015 Status changed from recruiting to discontinued.
- 23 Jan 2015 Status changed from not yet recruiting to recruiting.
- 23 Apr 2013 New trial record